Exbio — Research products — Antibodies — MHC antigens — Anti-HLA-A2 Purified Azide Free

Anti-HLA-A2 Purified Azide Free

Regulatory status

RUO

Antigen

HLA-A2

Clone

BB7.2

Format

Purified Azide Free

Reactivity

Human

Application

IP, FC (QC tested)

Variant

0.1 mg

10-556-C100

In stock

187.00 USD

0.025 mg

10-556-C025

Delivery 1 week

93.50 USD

Variant

0.1 mg

10-556-C100

In stock

187.00 USD

0.025 mg

10-556-C025

Delivery 1 week

93.50 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2b

Specificity

The antibody BB7.2 recognizes an extracellular epitope at the C-terminus of alpha-2 helix and a turn on one of the underlying beta strands within the human HLA-A2 histocompatibility antigen.

Application

IP, FC (QC tested)

Application details

Flow cytometry: Recommended dilution: 1 μg/ml.

Reactivity

Human

Immunogen

HLA-A2 solubilised by papain

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Antigen description

HLA-A2 (44 kDa) is the most frequent HLA-A allele in human ethnic populations. HLA-A, together with HLA-B and HLA-C, represent human HLA class I major histocompatibility (MHC) antigens. These intrinsic membrane glycoproteins are expressed on nucleated cells and noncovalently associate with an invariant beta2 microglobulin. They carry foreign determinants important for immune recognition by cytotoxic T cells, thus important for anti-viral and anti-tumour defence.

Flow cytometry analysis (surface staining) of human peripheral blood cells using anti-HLA-A2 (BB7.2) purified, GAM-APC.

Product specific references:

Lee L, Loftus D, Appella E, Margulies DH, Mage M: A recombinant single-chain HLA-A2.1 molecule, with a cis active beta-2-microglobulin domain, is biologically active in peptide binding and antigen presentation. Hum Immunol. 1996 Aug;49(1):28-37.
PubMed

Forero L, Zwirner NW, Fink CW, Fernández-Viña MA, Stastny P: Juvenile arthritis, HLA-A2 and binding of DEK oncogene-peptides. Hum Immunol. 1998 Jul;59(7):443-50.
PubMed

Verdegaal EM, Huinink DB, Hoogstraten C, Marijnissen AK, Gorsira MB, Claas FH, Osanto S: Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol. 1999 Dec;60(12):1195-206.
PubMed

Santin AD, Bellone S, Ravaggi A, Pecorelli S, Cannon MJ, Parham GP: Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells. Obstet Gynecol. 2000 Sep;96(3):422-30.
PubMed

Liang B, Zhu L, Liang Z, Weng X, Lu X, Zhang C, Li H, Wu X: A simplified PCR-SSP method for HLA-A2 subtype in a population of Wuhan, China. Cell Mol Immunol. 2006 Dec;3(6):453-8.
PubMed

Santos-Aguado J, Barbosa JA, Biro PA, Strominger JL: Molecular characterization of serologic recognition sites in the human HLA-A2 molecule. J Immunol. 1988 Oct 15;141(8):2811-8."
PubMed

Natali PG, Nicotra MR, Bigotti A, Venturo I, Marcenaro L, Giacomini P, Russo C: Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A. 1989 Sep;86(17):6719-23.
PubMed

Hogan KT, Brown SL: Localization and characterization of serologic epitopes on HLA-A2. Hum Immunol. 1992 Mar;33(3):185-92.
PubMed

Nijman HW, Houbiers JG, Vierboom MP, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJ, Kast WM: Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol. 1993 Jun;23(6):1215-9.
PubMed

Peoples GE, Goedegebuure PS, Andrews JV, Schoof DD, Eberlein TJ: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol. 1993 Nov 15;151(10):5481-91.
PubMed

Barouch D, Davenport M, McMichael A, Reay P: A mAb against HLA-A2 can be influenced both positively and negatively by the associated peptide. Int Immunol. 1995 Oct;7(10):1599-605.
PubMed

Scornik JC: HLA-A2 epitopes recognized by alloantibodies from broadly sensitized patients. Hum Immunol. 1987 Apr;18(4):277-85.
PubMed